UNSPSC 51401535: Nortetrazepam

This classification denotes a benzodiazepine with the molecular formula C15H15ClN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PWL441R6EQ, chemically known as 7-chloro-5-(1-cyclohexen-1-yl)-1,3-dihydro-2h-1,4-benzodiazepin-2-one but generally known as nortetrazepam, which bears US NIH Compound Identifier 166581. European Medicines Agency schedules Nortetrazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09379MIG.

UNSPSC 51401535 Nortetrazepam, a Commodity code, shows limited recent state and local procurement activity aligned with its nominal scope. The single documented opportunity under this code is Seminole County, Florida's IFB60459723LAS, posted June 30, 2026, which solicits naloxone and safe drug deactivation systems rather than nortetrazepam itself—a material mismatch between the code assignment and the work actually being procured. Seminole County, a county government issuing body, seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding to support community health initiatives, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. Vendors must include all shipping and delivery costs in their proposals, provide unit costs for each line item, maintain drug-free workplace and E-Verify compliance, and carry workers' compensation, commercial general liability, and professional liability insurance. The contract carries an initial two-year term with a one-year renewal option and includes a three-month probationary period during which the county may terminate with or without cause. FEMA funding introduces additional federal compliance obligations under the Clean Air Act and Federal Water Pollution Control Act.

The code shows minimal recent activity and no geographic spread beyond the single Seminole County, Florida opportunity; the July 26, 2023 response deadline for that IFB predates the current date by over three years, indicating no active or current state and local procurement under this code. The mismatch between the code's nominal pharmaceutical scope and the naloxone/drug-deactivation-system content of the documented opportunity suggests either a coding error in the source data or minimal use of this code in state and local procurement. Business development professionals should treat this code as inactive for current pursuit purposes and verify whether naloxone procurement is more accurately captured under a different UNSPSC category before committing resources to market development.